Navigation Links
Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance
Date:8/20/2010

ur ability to protect our intellectual property; a delay in qualifying our manufacturing facilities that produce our products or production or regulatory problems with either third party manufacturers or API suppliers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation, including domestic and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; our ability to realize the anticipated opportunities from our acquisition of the global branded pharmaceuticals business from The Procter and Gamble Company; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2009, and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive.  In addition, in light of these risks and uncertain
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
2. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
3. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
4. Warner Chilcott Announces 2010 Financial Guidance Conference Call
5. Warner Chilcott Announces Secondary Equity Offering
6. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
7. Warner Chilcott Prices Secondary Equity Offering
8. Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015
9. Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes
10. Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2010 Financial Results
11. Warner Chilcott to Present at the Bank of America Merrill Lynch Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Financial Highlights f or the ... : Revenues increased 58.1% to $24.2 million ... Net income rose 73.6% to $13.4 million, representing a net margin of 55.5% ... " ) increased to $0.80; Diluted EPS increased to $0.79 ...
... EMERYVILLE, Calif., March 28, 2011 Bionovo, Inc. (Nasdaq: ... and development of safe and effective treatments for women,s health ... Phase 1 clinical trial testing the safety of two doses ... hot flushes (study # MF101-008), also known as "menopausal hot ...
Cached Medicine Technology:Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 2Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 3Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 4Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 5Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 6Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 7Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 8Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 9Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes 2Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes 3
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
(Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...
(Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
(Date:7/9/2014)... from The Miriam Hospital have found that people ... also depressed have difficulty sticking to a pulmonary ... for women, and screening and brief treatment of ... The study and its findings are published in ... Chronic obstructive pulmonary disease is a common and ...
(Date:7/9/2014)... Montefiore Medical Center and the Albert ... present new findings at the Alzheimer,s Association International Conference ... Copenhagen, Denmark. Data from the four abstracts will focus ... to mild cognitive impairment and dementia. The research is ... in 1980 to examine healthy brain aging as well ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3
... of Nationwide Awareness Campaign - KENILWORTH, N.J., March ... SGP ), maker of the non-drowsy ... allergy sufferer and NASCAR driver Carl Edwards to ... News Release, go to: http://www.prnewswire.com/mnr/claritin/37512/ "Drowsy driving ...
... DENVER, March 18 St. Joseph,s Hospital in Marshfield, ... Medical Technologies, VersaRad CR radiography system. These units ... as for St. Joe,s Diagnostic Imaging services. St. Joseph,s ... of the Marshfield medical complex serving Wisconsin and the ...
... Northern California Chapter of the National MS SocietyMOUNTAIN VIEW, Calif., ... special donation program to coincide with MS Awareness ... a cure for multiple sclerosis. For each sale of a ... 2009, Presto Services Inc. will donate 5% of the retail ...
... TO ARMS 2009 EDITION" is a new documentary ... traces the controversial Anthrax Vaccine Immunization Program ( AVIP ... Through the personal invitation of Rick and Rozene ... Baristo Rd., Palm Springs, CA, the documentary feature had ...
... equipment to be acquired as part of purchaseMOUNTAIN VIEW, ... Los Gatos Town Council last evening, El Camino Hospital ... Camino Hospital had signed agreements that will allow an ... Los Gatos acquisition. The agreements will allow El ...
... March 17 Standard & Poor,s Rating Services (S&P) ... ,B, on Huntsman Corporation,s (NYSE: HUN ) ... that its operations are sound and that its liquidity ... Huntsman has met the challenging operating environment by ...
Cached Medicine News:Health News:Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM) 2Health News:Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM) 3Health News:Fischer Medical Announces Multi-System VersaRad Installation at St. Joseph's Hospital in Marshfield, WI 2Health News:Presto Announces Donation Program to Help Find the Cure for Multiple Sclerosis 2Health News:Presto Announces Donation Program to Help Find the Cure for Multiple Sclerosis 3Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 2Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 3Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 4Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 5Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 6Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 7Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 8Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 9Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 10Health News:Parties in Los Gatos Hospital Acquisition Agree on Terms Allowing El Camino Hospital an Early Close of Escrow 2Health News:Parties in Los Gatos Hospital Acquisition Agree on Terms Allowing El Camino Hospital an Early Close of Escrow 3Health News:Huntsman Responds to S&P Action 2Health News:Huntsman Responds to S&P Action 3
... Coagulation tubes contain a ... is available with a citrate ... or 0.129 mol/l (3.8%). The ... citrate solution to 9 parts ...
Plastic Citrate Tube, .109M / 3.2%...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: